INVA Research and Charts

INVA - Innoviva Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2026-02-10)

Last 21.84	Change ⇑ +0.21 (+0.97%)	Volume 690,776
	Open 21.63	High 21.99	Low 21.57

8EMA (Daily) 21.28	40EMA (Daily) 20.32	50EMA (Daily) 20.24	STO (Daily) 91.855	MACD Hist (Daily) 0.203
8EMA (Weekly) 20.634	40EMA (Weekly) 19.70	50EMA (Weekly) 19.49	STO (Weekly) 58.784	MACD Hist (Weekly) 0.179


Company Profile
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.